AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04242316 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Bilateral arm training
Description: Patients performed customized bimanual upper limb exercises with graded level of difficulty based on the patient's individual levels of upper limb functioning according to the 7 levels of the FTHUE and each level consisted of 5 standardized table-top tasks, but without a mirror. The patients can take a direct view of their paretic hand.
Study NCT04331327 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: allogenic lyophilized growth factors
Description: Prior to usage, reconstitution of the product was done using 1-ml saline and 1-ml lignocaine followed by gentle vial rubbing for 3 minutes. Then, the mixture was kept at ambient temperature for 5 minutes to ensure complete protein re-hydration.
Study NCT03269591 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Pulsed electromagnetic field
Description: EASY Qs portable (by ASA, Italy)
Study NCT03269591 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pulsed electromagnetic field
Description: EASY Qs portable (by ASA, Italy)
Study NCT03269591 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pulsed electromagnetic field
Description: EASY Qs portable (by ASA, Italy)
Study NCT03269591 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: diclofenac tablets
Description: drugs
Study NCT03269591 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: diclofenac tablets
Description: drugs
Study NCT03269591 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: diclofenac tablets
Description: drugs
Study NCT03269591 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Visual analogue scale
Description: a graphic rating scale
Study NCT03269591 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Visual analogue scale
Description: a graphic rating scale
Study NCT01635127 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Constituent of canakinumab
Study NCT00996918 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bapineuzumab 0.5 mg/kg
Description: Bapineuzumab I.V., 0.5 mg/kg, infusion every 13 weeks for a total of 16 infusions.
Study NCT00996918 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bapineuzumab 1.0 m/kg
Description: I.V., 1.0 mg/kg, infusion every 13 weeks for a total of 16 infusions.
Study NCT03269591 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Visual analogue scale
Description: a graphic rating scale
Study NCT03269591 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Progesterone blood level
Description: blood test
Study NCT03269591 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Progesterone blood level
Description: blood test
Study NCT03269591 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Progesterone blood level
Description: blood test
Study NCT03269591 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Menstrual symptom questionnaire
Description: questionnaire
Study NCT03269591 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Menstrual symptom questionnaire
Description: questionnaire
Study NCT03269591 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Menstrual symptom questionnaire
Description: questionnaire
Study NCT00397423 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Granulocyte Colony Stimulating Factor
Description: Granulocyte Colony Stimulating Factor,5ug/kg/day iH Qd\*5 days,3 months interval for 4 times
Study NCT00397423 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NS
Description: NS 1ml iH Qd\*5 days, 3 months interval for 4 times
Study NCT03549845 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cardiovascular Health Awareness Program
Description: Cardiovascular disease prevention and health promotion
Study NCT00629629 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietary Advice
Description: Step 1 - Provide Exclusive breastfeeding up to 6 mo.~Step 2- After 6 mo, gradually introduce complementary foods and continue breastfeeding up to 2 y or more.~Step 3 - Complementary foods should be given 3 times a day (cereals, beans, fruits, and vegetables) if the child is breastfed, and 5 times a day if not.~Step 4- Mealtimes must be adjusted to the children's cues of hunger and satiety.~Step 5: Foods should gradually get thicker up to the time when the child is able to eat a family meal. Complementary foods should not be liquefied.~Step 6: A large variety of healthy foods should be given daily to guarantee the intake of different nutrients.~Step 7: Different fruits and vegetables should be offered daily. Step 8: Sugar, sweets, soft drinks, salty snacks, cookies, and processed and fried foods must be avoided.~Step 9: Good hygiene practices in food preparation and handling.~Step 10: Adequate feeding during child illness.
Study NCT01832688 — intervention group
Intervention type: OTHER
Intervention: Programmatic prenatal care optimization
Description: To further integrate and improve nutrition-related services and messages in the prenatal care package.
Study NCT03345953 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BP 1.4979
Description: Double blind versus placebo
Study NCT03345953 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Double blind versus placebo
Study NCT03248778 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: disclosure-support counseling intervention
Description: The intervention will include three components: (a) assessment; (b) decision-making and support; and (c) disclosure, planning, and action. The individualized assessment comprehensively will consider the family's history, experiences with disclosure, communication skills, coping resources, and factors likely to affect disclosure (e.g., familial, psychological, social, cultural, and medical issues). The second component of decision-making and support focused on developing communication skills and strategies, with role-play and practice outside of the sessions as necessary. Costs and benefits of disclosure were considered along with the range of disclosure options. Materials, including a pros and cons chart of disclosure and a disclosure continuum worksheet, were used to stimulate discussions of possible plans and consequences. In the third component, parents were encouraged to formulate and practice a disclosure plan for later use.
Study NCT00391092 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab [Avastin]
Description: 15mg/kg iv every 3 weeks
Study NCT00391092 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 100mg/m2 iv every 3 weeks
Study NCT00391092 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: 100mg/m2 iv every 3 weeks
Study NCT00391092 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Herceptin
Description: 8mg/kg iv loading dose, followed by 6mg/kg iv every 3 weeks
Study NCT00391092 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Herceptin
Description: 8mg/kg iv loading dose, followed by 6mg/kg iv every 3 weeks
Study NCT04329013 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Left lateral Position during intervention
Description: Left lateral position during EGD
Study NCT04329013 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prone Position during intervention
Description: Prone position during EGD
Study NCT02591316 — intervention group
Intervention type: OTHER
Intervention: no intervention
Study NCT02282826 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GZ402668
Description: Pharmaceutical form:solution Route of administration: intravenous
Study NCT03526913 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PRP
Description: PRP: autologous platelet-rich plasma
Study NCT03526913 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: STSG
Description: skin graft: Split Thickness Skin Grafting (STSG)
Study NCT03526913 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: STSG
Description: skin graft: Split Thickness Skin Grafting (STSG)
Study NCT00701051 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic exercise training
Description: 24 weeks of aerobic exercise training: 3 times per week, 60 minutes per session, at 70% of maximal aerobic capacity
Study NCT00701051 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic exercise training
Description: 24 weeks of aerobic exercise training: 3 times per week, 60 minutes per session, at 70% of maximal aerobic capacity
Study NCT00701051 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Detraining (cessation of exercise)
Description: Cessation of exercise for 2 weeks
Study NCT00701051 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Detraining (cessation of exercise)
Description: Cessation of exercise for 2 weeks
Study NCT04112849 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Measurement of S3 heart sound
Description: S3 heart sound to be measured by Nanowear Congestive Heart Failure Management System device.
Study NCT02923037 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Yoga
Description: Complete guided and home yoga sessions
Study NCT02923037 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: tape measurement of arm
Description: Ancillary studies
Study NCT02923037 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT02923037 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ldex measurement of arms
Study NCT02073968 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV
Study NCT02073968 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo PET-adjusted IMRT
Study NCT02073968 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity-Modulated Radiation Therapy
Description: Undergo PET-adjusted IMRT
Study NCT02073968 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV
Study NCT02073968 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET-adjusted IMRT
Study NCT02073968 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Proton Beam Radiation Therapy
Description: Undergo proton beam radiation therapy
Study NCT03892941 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Imaged based fitting
Description: Mapping of the electrical input of the cochlear implant will be based on an individualized natural frequency alignment as estimated with imaging methods.
Study NCT04363905 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 100 mg lactose per day for 6 weeks
Study NCT04363905 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ferrous sulfate
Description: 20 mg per day of elemental iron for 6 weeks
Study NCT03532789 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: herbal patch
Description: One patch with medicine should be applied to the skin every other day within two weeks
Study NCT03532789 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo patch
Description: One patch without medicine should be applied to the skin every other day within two weeks
Study NCT03956602 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pretzels
Description: To examine postprandial responses of pretzel consumption
Study NCT03956602 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Brazil nuts
Description: To examine postprandial responses of Brazil nut consumption
Study NCT03956602 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Potato chips
Description: To examine postprandial responses of potato chip consumption
Study NCT03956602 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mixed nuts
Description: To examine postprandial responses of mixed nut consumption
Study NCT03956602 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: White bread
Description: To examine postprandial responses of white bread consumption
Study NCT03956602 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dried mango
Description: To examine postprandial responses of dried mango consumption
Study NCT03956602 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mango fruit
Description: To examine postprandial responses of fresh mango consumption
Study NCT02745626 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Appliance
Description: Orthodontic appliance to carry out orthodontic tooth movement.
Study NCT02005341 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: nanOSS
Study NCT02005341 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Autograft
Study NCT02647359 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ataluren
Description: Ataluren oral suspension will be administered as per the dose and schedule specified in the respective arms.
Study NCT02647359 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ataluren
Description: Ataluren oral suspension will be administered as per the dose and schedule specified in the respective arms.
Study NCT02647359 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered as per the schedule specified in the respective arm.
Study NCT01731171 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic Supplement
Description: Probiotic Supplement 1 tablet by mouth daily
Study NCT01731171 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Inert Compound
Description: Probiotic identical placebo 1 tablet by mouth daily
Study NCT03795844 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: liver retraction Nathanson retractor
Description: liver retractor will be used for the retraction of left lobe of liver
Study NCT03795844 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: liver retraction snake retractor
Description: liver retractor will be used for the retraction of left lobe of liver
Study NCT03795844 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: liver retraction fan retractor
Description: liver retractor will be used for the retraction of left lobe of liver
Study NCT03795844 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: liver retraction laparoscopic grasper
Description: laparoscopic grasper without any special tools
Study NCT03310541 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5363
Description: AZD5363 400mg PO twice daily for 4 days on, 3 days off, every week
Study NCT03310541 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: Enzalutamide 160 mg PO once daily
Study NCT03310541 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: 500mg IM days 1, 15, 29 (cycle 2 day 1) and then every 4 weeks
Study NCT01884298 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: remifentanil(Ultiva)
Description: remifentanil (TCI, Ce 3 ng /ml)for intra-operative analgesia
Study NCT01884298 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: epidural infusing 2% lidocaine
Description: epidural infusing 2% lidocaine 4ml bolus followed by 6-18ml/hr for intra-operative analgesia
Study NCT01470027 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: N-acetylcysteine
Description: 900mg NAC effervescent tablets
Study NCT01470027 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: effervescent tablets
Study NCT03402243 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Menthol ban on cigarettes
Description: Participants will have menthol and tobacco flavored e-cigarettes available but only non-menthol cigarettes
Study NCT03402243 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Menthol ban on cigarettes and e-cigarettes
Description: Participants will have neither menthol flavored cigarettes or e-cigarettes available
Study NCT03402243 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: No menthol ban
Description: Participant will have menthol and tobacco flavored cigarettes and e-cigarettes available
Study NCT01993524 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: probiotic
Description: antibiotic plus probiotic
Study NCT01993524 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: antibiotic plus placebo
Study NCT01040130 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olodaterol (BI 1744)
Description: Comparison of low and high doses on exercise endurance time in COPD patients
Study NCT01040130 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Comparison of low and high dose and placebo on exercise endurance time in COPD patients
Study NCT01040130 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olodaterol (BI 1744)
Description: Comparison of low and high dose
Study NCT01040130 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olodaterol (BI 1744) Placebo
Description: Placebo that represents olodaterol
Study NCT00881725 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: 500mg tablets t.i.d. for 4-12 weeks prior to Radical Prostatectomy
Study NCT01584063 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy MOMs Healthy Lifestyle Intervention
Description: These women received the culturally tailored Healthy MOMs Healthy Lifestyle Intervention, which included social support from Women's Health Advocates (community health workers) and peers, and the Healthy MOMs curriculum. This intervention curriculum covered topics related to healthy eating, physical activity, and stress management during pregnancy and postpartum. General information about pregnancy and the postpartum period were also provided. This intervention was delivered during 10 group meetings and 4 home visits.
Study NCT02083523 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Motivational Interview with Normative Feedback
Description: NOrmative Feedback (NF) contrasts and individual's substance use to available norms for one's reference group (i.e., descriptive norms.) Essentially, NF highlights how an individual's behavior is non-normative, which in turn, is thought to lead to reduced substance use.
Study NCT02083523 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Motivational Interview
Description: The Motivational Interview (MI) addresses ambivalence about change. It's effects are mediated by how well counselors evoke change talk, or in-session client utterances about the: need for; commitment to; ability to; or steps needed, to change.
Study NCT03727893 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Roller-based Intervention Group (IG)
Description: A group of manual wheelchair users (MWUs) with spinal cord injury (SCI) that will complete an initial exercise education and a 12-week (3 sessions per week) evidence-based high-intensity interval training (HIIT) program using the roller-based WheelMill (WMS) system.
Study NCT03727893 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control Group (CG)
Description: A group of manual wheelchair users (MWUs) with spinal cord injury (SCI) that will complete an initial exercise education session and enroll in a 12-week (3 sessions per week) independent workout program at an accessible community-based fitness facility.
Study NCT02863016 — intervention group
Intervention type: DEVICE
Intervention: SelectBag One
Description: Each patient will be subjected to two stages of each month, where it will be treated with online HDF postdilution with two kind of concentrates: acetic acid (Ac-HDF) and acetate-free citrate containing one (HDF-Cit ). For each of the sessions will be used online HDF postdilution with TMP biofeedback (UltraControl) and Filter high permeability.
Study NCT03207750 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Rotarix
Description: Two doses administered orally according to a 0, 2 month schedule as per the immunization schedule for HRV vaccine administration in the US.
Study NCT03207750 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rotarix
Description: Two doses administered orally according to a 0, 2 month schedule as per the immunization schedule for HRV vaccine administration in the US.
Study NCT03207750 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pediarix
Description: Three doses administered intramuscularly according to a 0, 2, 4 month schedule.
Study NCT03207750 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pediarix
Description: Three doses administered intramuscularly according to a 0, 2, 4 month schedule.
Study NCT03207750 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Hiberix
Description: Three doses administered intramuscularly according to a 0, 2, 4 month schedule.
Study NCT03207750 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hiberix
Description: Three doses administered intramuscularly according to a 0, 2, 4 month schedule.